200 related articles for article (PubMed ID: 2516350)
1. Adjuvant chemotherapy for node-negative breast cancer patients.
Bonadonna G; Zambetti M; Valagussa P
Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
[No Abstract] [Full Text] [Related]
2. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
Jakesz R; Reiner G; Schemper M; Reiner A; Blijham G; Rainer H; Dittrich D; Spona J; Schutte B; Reynders M
Recent Results Cancer Res; 1989; 115():180-5. PubMed ID: 2696031
[No Abstract] [Full Text] [Related]
3. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
Jonat W; Kaufmann M; Abel U
Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028
[No Abstract] [Full Text] [Related]
4. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
Wallgren A; Baral E; Beling U; Carstensen J; Friberg S; Glas U; Kaigas M; Skoog L
Recent Results Cancer Res; 1984; 96():197-203. PubMed ID: 6396775
[No Abstract] [Full Text] [Related]
6. Adjuvant immunotherapy in node-negative patients: results of a Scandinavian study.
Nissen-Meyer R; Host H; Kjellgren K
Recent Results Cancer Res; 1989; 115():186-90. PubMed ID: 2696032
[No Abstract] [Full Text] [Related]
7. Adjuvant therapy in primary breast cancer.
Wolmark N; Fisher B
Surg Clin North Am; 1985 Feb; 65(1):161-80. PubMed ID: 3887616
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Rossi A; Brambilla C; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772
[No Abstract] [Full Text] [Related]
9. Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.
Brambilla C; Rossi A; Valagussa P; Bonadonna G
World J Surg; 1985 Oct; 9(5):728-37. PubMed ID: 3840630
[No Abstract] [Full Text] [Related]
10. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
11. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
World J Surg; 1985 Oct; 9(5):723-7. PubMed ID: 3840629
[No Abstract] [Full Text] [Related]
12. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
13. Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Henderson IC
J Clin Oncol; 1985 Feb; 3(2):140-3. PubMed ID: 3881560
[No Abstract] [Full Text] [Related]
14. Hormone receptors. An update and application.
Hubay CA; Arafah B; Gordon NH; Guyton SP; Crowe JP
Surg Clin North Am; 1984 Dec; 64(6):1155-72. PubMed ID: 6393400
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
Kaufmann M; Jonat W; Abel U
Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024
[No Abstract] [Full Text] [Related]
16. Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
Scheurlen H
Recent Results Cancer Res; 1989; 115():226-35. PubMed ID: 2696037
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
[TBL] [Abstract][Full Text] [Related]
19. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
[No Abstract] [Full Text] [Related]
20. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
